uploads///Graph

Pfizer’s Eliquis Sees Double-Digit Revenue Growth Year-to-Date

Margaret Patrick - Author
By

Nov. 6 2018, Updated 7:30 a.m. ET

Eliquis revenue growth trends

Pfizer (PFE) and Bristol-Myers Squibb’s (BMY) Eliquis continues to be a dominant player in the novel oral anticoagulant (or NOAC) class of drugs.

According to Pfizer’s third-quarter earnings conference call, the drug has already surpassed warfarin in this segment in the US market in terms of total prescription share.

In the first nine months of 2018, Pfizer reported alliance and direct sales revenue of $2.52 billion for Eliquis, a YoY (year-over-year) rise of 39% on a reported basis and 36% on an operational basis. Of this revenue, $1.37 billion was earned from the US market, reflecting a YoY rise of 32%. International markets contributed $1.15 billion worth revenue, a YoY rise of 49% on a reported basis and 42% on an operational basis.

In the international market, the company reported revenue of $692 million for Eliquis in Western Europe, Finland, and Scandinavian countries in the first nine months of 2018, a YoY rise of 59% on a reported basis and 48% on an operational basis.

Pfizer also reported revenue of $240 million in other developed markets such as Japan, New Zealand, South Korea, Australia, and Canada, a YoY rise of 21% on a reported basis and 18% on an operational basis.

Article continues below advertisement

Third-quarter performance

In the third quarter, Pfizer reported alliance and direct sales revenue of $870 million for Eliquis, a YoY rise of 35% on a reported basis and 36% on an operational basis. Of this revenue, $455 million was earned from the US market, reflecting a YoY rise of 29%. International markets contributed $416 million worth of revenue, a YoY rise of 43% on a reported basis and 44% on an operational basis.

In the next article, we’ll discuss the growth trends for Pfizer’s Xeljanz in greater detail.

Advertisement

Latest Pfizer Inc News and Updates

    © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.